Back
Previous product
IGF-1 LR3 1mg $89.99 $59.99
Next product
Sermorelin 2mg Sermorelin Peptide(2mg) $39.99 $34.99
Click to enlarge

CJC-1295 2mg (with DAC)

$39.99

FOR RESEARCH PURPOSES ONLY

CJC-1295 is a modified version of growth hormone releasing factor (GRF) where four amino acids have been replaced: position 2 with D-Ala, position 8 with Gln, position 15 with Ala, and position 27 with Leu. These substitutions result in a much more stable peptide, with the substitution at position 2 preventing DPP-IV cleavage, position 15 increasing bioactivity, position 8 reducing amide hydrolysis or asparagine rearrangement to aspartic acid and position 27 preventing methionine oxidation.

By using Drug Affinity Complex (DAC) technology on GRF, the peptide covalently and selectively binds to circulating albumin following subcutaneous (SC) administration, extending its half-life.

*The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

Out of stock

SKU: CJC1295 Category: Tag:
Description

Description

FOR RESEARCH PURPOSES ONLY

CJC-1295 DAC is a synthetic version of growth hormone releasing factor (GRF) where certain molecular positions have been altered. When combined with DAC, this modification extends how long the compound remains active in the body and allows it to bind more effectively to albumin (a blood protein).

CJC-1295 is a modified version of the growth hormone releasing factor (GRF) that replaces four amino acids: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.

These substitutions result in a much more stable peptide, with the substitution at 2 position preventing DPP-IV cleavage, position 15 increasing bioactivity, position 8 reducing amide hydrolysis to aspartic acid or asparagine rearrangement, and position 27 preventing methionine oxidation.

Using Drug Affinity Complex (DAC) technology on GRF, the peptide covalently and selectively binds to circulating albumin after subcutaneous (SC) administration. This can increase its half-life. The substitutions increase the half-life of CJC-1295 from ~7 minutes to more than 7 days.

Bioconjugation is a relatively new technology that attaches a reactive group to a peptide, which then reacts with a nucleophilic (typically a partially negative molecule) entity in the blood to form a more stable bond. This peptide selects albumin, one of the most prevalent substances in the human body, as the nucleophile because of its appealing Cys34 thiol group.

The tetrasubstituted GHRH analogue is combined with maleimodoproprionic acid via a Lys linker to produce a GHRH peptide with a high albumin binding affinity. Albumin prevents enzymatic degradation and kidney excretion, so the CJC-1295 molecule has a longer half-life and bioavailability once attached.

In fact, bioconjugation is so effective that less than 1% of CJC-1295 remains unreacted in vivo. In contrast, more than 90% of patients were stabilized following subcutaneous injection. This means you get more value for your money. DPP-IV degradation was not observed on CJC-1295 in any of the experiments.